Faron Pharmaceuticals specializes in developing drugs that target endothelium receptors. These blood vessel-found proteins assist in regulating the immune response. The business is currently working on two small molecule therapeutic candidates that have the potential to treat a variety of illnesses, such as cancer, infectious diseases, respiratory ailments, and multi-organ failure. The phase III acute respiratory distress syndrome studies for the most advanced program are now complete.

Acute Respiratory Distress Syndrome (ARDS) is a condition that is treated with the company's flagship medication, Traumakine. After an open-label, early-phase trial produced encouraging results in the treatment of patients with ARDS, it is currently (2020) undertaking worldwide phase III clinical trials. Vascular leakage and the escalation of inflammation are decreased as a result of the medication's ability to increase lung CD73 expression and increase the synthesis of the anti-inflammatory compound adenosine. The planned protocol design for the next Traumakine research, which will begin in March 2020, has been approved by the U.S. Food and Drug Administration FDA. The phase III trial compares the effectiveness of several treatments for ARDS patients. Faron Pharmaceuticals is one of the largest biotech companies in Finland.

Headquarters: Turku

Founded: 2003

Website: https://www.faron.com/

MetGen is a biotechnology company that specializes in the development and application of enzyme technologies for various industries, including the biofuels, biochemicals, and pulp and paper sectors. The company focuses on harnessing the power of enzymes to enable sustainable and efficient processes. Founded in 2008, Metgen is a Finnish SME with 12 employees. Metgen provides enzymatic solutions that enable industry to maximise the benefits of biomass.

MetGen creates renewable alternatives to the products that are now created using petrochemical methods by utilising genetic engineering and synthetic biology. The MetGen team possesses the skills necessary to modify enzymes for harsh industrial environments, as well as vast experience in genetic engineering and microbiology. The business has created enzymes that enable the production of chemicals, biofuels, and paper using wood waste as the raw material. MetGen hopes to use this technology to generate industrial chemicals with no prices, little waste, and little energy.

Headquarters: Kaarina
Founded: 2008

Website: https://www.metgen.com/

One of the largest biotech companies in Finland is Forendo Pharma. It is a biopharmaceutical company focused on the development of innovative treatments for endometriosis and other hormone-driven inflammatory diseases. The company is based in Finland and was founded in 2013.

Endometriosis, a disorder of the uterus that results in excruciating pain and infertility, is treated by Forendo Pharma. Small molecule medication candidates are being developed by the company that is intended to work locally rather than altering hormone levels throughout the body as do current therapies. Phase I trials for the most advanced program is now taking place. Forendo Pharma is dedicated to addressing the unmet medical needs in this field by developing novel therapeutics targeting the underlying mechanisms of endometriosis.

Forendo Pharma's approach involves targeting tissue-specific enzyme systems that are involved in the production and metabolism of hormones, particularly estrogen. By modulating these enzyme systems, the company aims to develop treatments that can reduce the inflammation and associated symptoms of endometriosis.

In order to focus on enhancing women's health throughout their lives, Organon was created as a spin-off from Merck, which is known as MSD outside of the United States and Canada. In December 2021, Organon announced the completion of the acquisition of Forendo Pharma

Headquarters: Turku, Western Finland, Finland
Founded: 2013
Website: https://www.organon.com/news/organon-to-acquire-forendo-pharma/

Blueprint Genetics is a genetic testing company that specializes in providing comprehensive genetic diagnostics for various inherited disorders and rare diseases. The company was founded in 2012 and is headquartered in Helsinki, Finland, with offices and laboratories in several countries worldwide.

To assist doctors in making a genetic disease diagnosis for patients, Blueprint Genetics creates and markets genetic tests. The company provides a wide range of tests that span thousands of genes across numerous illness categories, and it also has experts on staff who can analyze the data and suggest the next steps. Early in 2020, Quest Diagnostics purchased the business; since then, it has continued to run out of its Helsinki headquarters.

Blueprint has already been able to enhance productivity with the new solution by 30 to 50%, and as its analysts develop more expertise, they hope to see a three-fold increase in processing speed and capacity. Additionally, compared to the 30-day delivery time of its rivals, it can offer patient outcomes in 14 to 21 days.

In addition to genetic testing services, Blueprint Genetics also provides genetic counseling support to healthcare professionals and patients, helping them understand the test results, their implications, and the potential treatment options available.

Headquarters: Helsinki
Founded: 2012
Website: https://blueprintgenetics.com/

Herantis Pharma is a biopharmaceutical company focused on developing innovative therapies for diseases with high unmet medical needs. The company is based in Finland and was founded in 2008.

Herantis Pharma is primarily focused on developing treatments for neurodegenerative diseases and fibrotic diseases. Their pipeline includes investigational drugs targeting diseases such as Parkinson's disease, Alzheimer's disease, and secondary lymphedema.

Herantis Pharma, which has been traded on Nasdaq Helsinki since 2014, intends to cure the underlying causes of diseases that are challenging to treat as well as their symptoms. The most advanced programme of the company is a gene therapy for breast cancer-associated lymphedema, an abnormal swelling that can arise from cancer treatments. It is currently in phase II. A Parkinson's disease treatment that aims to prevent neurons from deteriorating and to regenerate those that have already been harmed is also being tested by Herantis in phase I/II clinical trials.

Headquarters: Espoo

Founded: 2008

Website: https://herantis.com/

Solar Foods is a Finland company that is pioneering a novel approach to food production by using renewable energy and microbial fermentation. The company aims to create a sustainable and environmentally friendly alternative to traditional agriculture and food production methods.

A new company called Solar Foods has a lofty ambition: to create meals solely from water, air, power, and microorganisms. The outcome is a protein-rich powder that might be utilized to make meat substitutes or to grow meat in a lab. Additionally, the business is collaborating with the European Space Agency to explore this technology as a novel approach to food production that might greatly lessen waste and weight on lengthy space trips.

Solar Foods has developed a technology called "Solein," which involves using electricity from renewable sources, such as solar or wind energy, to power a fermentation process that converts carbon dioxide (CO2) into edible proteins. The process utilizes microbes that are capable of converting CO2 and hydrogen into a protein-rich powder that can be used as a versatile ingredient in various food products.

Headquarters: Helsinki

Founded: 2017

Website: https://solarfoods.com/

The industry leader in biodegradable silica-based controlled release of small molecule medications, biopharmaceuticals, and viral vectors is Delsitech which is one of the largest biotech company in Finland. The Biomaterial Research Group at the University of Turku and Ko Akademi University in Turku, Finland, created the technology, which is wholly owned and patented by DelSiTech.

Delsitech seeks to lessen the negative side effects of generic medications while increasing their efficacy. The business can do this by encapsulating the active ingredient in a silica matrix that is designed to release the medication into the body at the specified time interval, which can be anything between one day and up to a year. Entecavir, a daily-prescribed antiviral medication for hepatitis B, is the focus of the main program. The medicine might now be administered every three months thanks to Delsitech's delivery system, which would assist patients stick to their treatment regimen. The business also makes its technologies available to associate drug developers.

Headquarters: Turku

Founded: 2001

Website: https://www.delsitech.com/

Nanoform is a Finland nanotechnology company that specializes in enhancing the bioavailability and solubility of pharmaceutical compounds through its proprietary technology platform. The company was founded in 2015 and is headquartered in Helsinki, Finland.

The company collaborates with pharmaceutical companies to apply its canonization technology to their drug candidates, aiming to improve their therapeutic profiles and clinical outcomes. Nanoform's approach can be particularly beneficial for poorly soluble drugs that have limited absorption or efficacy due to their low bioavailability.

Nanoform specializes in enhancing drug candidate performance through the use of nanoparticles. There are a lot of novel compounds with potential for medicine that are difficult to dissolve, making it difficult for the medications to reach the patient's bloodstream and have the desired effect. The Nanoform particles are made to make these molecules more soluble so they can enter clinical trials and make the formulation process easier. According to the business, this technique may potentially treble the pharmaceutical industry's yearly output of new pharmaceuticals.

Headquarters: Helsinki

Founded: 2015

Webiste: https://nanoform.com

Aiforia is a Finland software company that specializes in artificial intelligence (AI)-powered image analysis solutions for digital pathology and medical research. The company was founded in 2013 and is headquartered in Helsinki, Finland. This company is one of the largest biotech companies in Finland.

Aiforia develops advanced deep learning algorithms and software tools that enable efficient and accurate analysis of digital pathology images. Their platform allows pathologists and researchers to analyze and interpret large volumes of image data more effectively, leading to improved diagnostic accuracy and faster insights.

Aiforia specializes in creating unique AI techniques to support picture analysis in medical research. According to the business, this can remove the significant variability seen when various people analyse the photos and cut the time needed to analyze medical images by 90% when compared to manual approaches. The models are created especially for each client's needs and have been used to study a wide range of specialties, such as cancer, liver disease, infections, and neuroscience.

Headquarters: Helsinki

Founded: 2013

Website: https://www.aiforia.com/

Mobidiag is a Finnish biotechnology company that specializes in developing and providing innovative molecular diagnostic solutions for infectious diseases. The company was founded in 2000 and has since become a leading player in the field of rapid and multiplexed diagnostics.

Mobidiag's primary focus is on developing and commercializing molecular diagnostics tests for detecting and identifying various pathogens, including bacteria, viruses, and parasites. Their solutions are designed to provide rapid and accurate results, enabling healthcare professionals to make informed treatment decisions more quickly.

One of Mobidiag's notable products is the Amplidiag® platform, which consists of a range of diagnostic tests and instruments. The Amplidiag platform utilizes real-time polymerase chain reaction (PCR) technology to detect and identify multiple pathogens simultaneously from a single patient sample. This multiplexing capability allows for efficient and comprehensive testing, particularly in the context of infectious disease outbreaks.

Mobidiag's molecular diagnostic solutions have been used in the detection and management of various infectious diseases, including gastrointestinal infections, respiratory tract infections, and antibiotic-resistant bacteria. Their technologies offer the potential for faster and more accurate diagnosis, leading to improved patient care and better antimicrobial stewardship.

Headquarters: Helsinki: Espoo

Founded: 2000

Website: https://mobidiag.com/